Delray Beach, FL, May 05, 2025 (GLOBE NEWSWIRE) — The global Gene Therapy market, valued at US$7.21 billion in 2023, is forecasted to grow at a robust CAGR of 19.4%, reaching US$8.85 billion in 2024 and an impressive US$36.55 billion by 2032. Market growth is attributed to factors such as the growing demand for curative therapies for genetic disorders, rare diseases, and specific types of cancer, robust clinical trial pipeline for gene therapy and increasing investments in gene therapy research. For instance, according to M&M, around 19 gene therapy products are expected to be launched between 2026 to 2032, and which will contribute closely to 25% of the 36.55 B market in 2032.
However, high cost of gene therapy products and Complex regulatory frameworks and ethical concerns regarding genetic modifications are expected to hinder the market growth over the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962
Browse in-depth TOC on “Gene Therapy Market“
660 – Tables
60 – Figures
433 – Pages
Based on therapy type, the gene therapy market is segmented into gene silencing therapy, cell replacement therapy, gene augmentation therapy and other therapies. The gene silencing therapy segment accounted for the largest share of the gene therapy market. This can be owing to the availability of many approved and commercialized gene therapies employing gene silencing mechanism of action in the current market, effectiveness of gene silencing mechanism against major indications in neurology.
Among vector segment, the gene therapy market is segmented into viral vectors and non-viral vector. The viral vectors segment accounted for the largest share of the gene therapy market. The large share of this segment can be owing to the high market penetration of viral vector-based gene therapies and advantages of viral vectors over non-viral vectors.
Among scale of operation segment, the gene therapy market is segmented into manufacturing-scale operations, pilot-scale operations, and R&D-scale operations. The manufacturing-scale operations segment accounted for the largest share of the gene therapy market. The large share of this segment can be owing to the growth in biologics and biosimilar manufacturing. Additionally, increasing number of biopharmaceuticals receiving regulatory approvals for production and the launch of biosimilars in the market is propelling the growth of the segment in gene therapy market.
Among gene type segment, the gene therapy market is segmented into deficiency, receptors, antigen, cytokine, tumour suppressor, other gene. The deficiency segment accounted for the largest share of the gene therapy market. Increasing amount of prevalence of rare genetic disorders caused due to deficiency of gene type, and approval of gene therapies for such rare diseases are the major factors driving the growth of this segment.
Based on region, The gene therapy market is segmented by region into six key regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. …